Study M011
Study name | Kaddurah-Daouk R 2011 |
Title | Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept |
Overall design | Outpatients with MDD were randomly assigned to sertraline (up to 150 mg per day) (sertraline group, n = 43) or placebo (placebo group, n = 46) in a double-blind 4-week trial. Baseline serum samples were profiled using the liquid chromatography electrochemical array; the output was digitized to create a "digital map" of the entire measurable response for a particular sample. Responder was defined as >= 50% decrease in HAMD-17 scores at week 4, and non-responders was defined as <50% decrease in HAMD-17 scores at week 4. Pretreatment metabotypes may predict which depressed patients will respond to acute treatment (4 weeks) with sertraline or placebo. |
Study Type | Type4; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive disorder; Depression; Depression; |
Criteria for depression | DSM-IV diagnosed MDD, HAMD-17 > 22 |
Sample size | 89 |
Tissue | Peripheral; Blood; Serum; |
Platform | MS-based; LCECA: Liquid chromatography electrochemical array (LCECA) platform; |
PMID | |
DOI | |
Citation | Kaddurah-Daouk R, Boyle SH, Matson W, et al. Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. Transl Psychiatry 2011;1.e26. |
Metabolite | L-Cysteine; 5-Hydroxyindoleacetic acid; Indoleacetic acid; 3,4-Dihydroxybenzeneacetic acid; Hydroxyphenyllactic acid; Serotonin; Gamma-Tocopherol; Hypoxanthine; Uric acid; Vanillylmandelic acid; Homogentisic acid; |
